Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-GPNMB Recombinant Antibody (CBFYH-0451) (CBMAB-H1326-FY)


See all GPNMB antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYH-0451
Antibody Isotype
IgG1
Application
WB

Basic Information

Immunogen
Full length human recombinant protein of human GPNMB produced in HEK293T cell
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
1 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Glycoprotein Nmb
Introduction
The protein encoded by this gene is a type I transmembrane glycoprotein which shows homology to the pMEL17 precursor, a melanocyte-specific protein. GPNMB shows expression in the lowly metastatic human melanoma cell lines and xenografts but does not show expression in the highly metastatic cell lines. GPNMB may be involved in growth delay and reduction of metastatic potential. Two transcript variants encoding different isoforms have been found for this gene.GPNMB (Glycoprotein Nmb) is a Protein Coding gene. Diseases associated with GPNMB include Melanoma and Glioblastoma Multiforme. Among its related pathways are Signaling by GPCR and Signaling by PTK6. Gene Ontology (GO) annotations related to this gene include heparin binding and integrin binding. An important paralog of this gene is PMEL.Could be a melanogenic enzyme.
Entrez Gene ID
10457
UniProt ID
Q14956
Alternative Names
Glycoprotein Nmb; Hematopoietic Growth Factor Inducible Neurokinin-1; Glycoprotein Nonmetastatic Melanoma Protein B; Glycoprotein (Transmembrane) Nmb; Transmembrane Glycoprotein HGFIN; Glycoprotein Nmb-Like Protein; Glycoprotein NMB
Function
Could be a melanogenic enzyme.
Biological Process
Bone mineralization Source: Ensembl
Cell adhesion Source: GO_Central
Cell-cell signaling Source: ParkinsonsUK-UCL
Negative regulation of cell population proliferation Source: ProtInc
Negative regulation of cytokine production Source: ParkinsonsUK-UCL
Negative regulation of G1/S transition of mitotic cell cycle Source: ParkinsonsUK-UCL
Negative regulation of neuron death Source: ParkinsonsUK-UCL
Negative regulation of T cell activation Source: ParkinsonsUK-UCL
Negative regulation of T cell proliferation Source: ParkinsonsUK-UCL
Negative regulation of tumor necrosis factor production Source: Ensembl
Osteoblast differentiation Source: Ensembl
Positive chemotaxis Source: ParkinsonsUK-UCL
Positive regulation of cell migration Source: ParkinsonsUK-UCL
Positive regulation of ERK1 and ERK2 cascade Source: ParkinsonsUK-UCL
Positive regulation of protein autophosphorylation Source: ParkinsonsUK-UCL
Positive regulation of protein phosphorylation Source: ParkinsonsUK-UCL
Regulation of angiogenesis Source: ParkinsonsUK-UCL
Regulation of tissue remodeling Source: ParkinsonsUK-UCL
Signal transduction Source: ParkinsonsUK-UCL
Cellular Location
Cell membrane; Early endosome membrane; Melanosome membrane. Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
Involvement in disease
Increased expression levels in glioblastoma multiforme biopsy samples correlate with poor patient survival prognosis (PubMed:16609006). Has been proposed as a potential target for antibodies coupled to cytotoxic drugs in the context of cancer immunotherapy, including that of melanoma (PubMed:16489096).
Amyloidosis, primary localized cutaneous, 3 (PLCA3):
A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins. PLCA3 inheritance is autosomal recessive.
Topology
Extracellular: 23-498
Helical: 499-519
Cytoplasmic: 520-572
More Infomation

Lazaratos, A. M., Annis, M. G., & Siegel, P. M. (2022). GPNMB: a potent inducer of immunosuppression in cancer. Oncogene, 41(41), 4573-4590.

Diaz-Ortiz, M. E., Seo, Y., Posavi, M., Carceles Cordon, M., Clark, E., Jain, N., ... & Chen-Plotkin, A. S. (2022). GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein. Science, 377(6608), eabk0637.

Saade, M., Araujo de Souza, G., Scavone, C., & Kinoshita, P. F. (2021). The role of GPNMB in inflammation. Frontiers in Immunology, 12, 674739.

Nickl, B., Qadri, F., & Bader, M. (2021). Anti-inflammatory role of Gpnmb in adipose tissue of mice. Scientific Reports, 11(1), 19614.

Liguori, M., Digifico, E., Vacchini, A., Avigni, R., Colombo, F. S., Borroni, E. M., ... & Belgiovine, C. (2021). The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. Cellular & Molecular Immunology, 18(3), 711-722.

Budge, K. M., Neal, M. L., Richardson, J. R., & Safadi, F. F. (2020). Transgenic overexpression of GPNMB protects against MPTP-induced neurodegeneration. Molecular Neurobiology, 57, 2920-2933.

Silva, W. N., Prazeres, P. H., Paiva, A. E., Lousado, L., Turquetti, A. O., Barreto, R. S., ... & Birbrair, A. (2018). Macrophage‐derived GPNMB accelerates skin healing. Experimental dermatology, 27(6), 630-635.

Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O., & Hallett, P. J. (2018). The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiology of disease, 120, 1-11.

Neal, M. L., Boyle, A. M., Budge, K. M., Safadi, F. F., & Richardson, J. R. (2018). The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. Journal of neuroinflammation, 15(1), 1-14.

Taya, M., & Hammes, S. R. (2018). Glycoprotein non-metastatic melanoma protein B (GPNMB) and cancer: a novel potential therapeutic target. Steroids, 133, 102-107.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-GPNMB Recombinant Antibody (CBFYH-0451)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry